HENDERSON, NV / ACCESSWIRE / November 12, 2018 / Opioids are a scourge companies across several sectors are looking to help eradicate. Pain relief options are popping up left and right in an attempt to replace the opioids doctors have been prescribing for years. Below are several companies that could be the solution to this major problem
The first on our list is Endonovo Therapeutics, Inc. (ENDV). ENDV has an extremely promising non-invasive pain reduction treatment therapy called SofPulse that could be the answer for larger companies looking at opioid alternative pain relief solutions.
ENDV recently concluded a study on SofPulse’s effectiveness in treating nonalcoholic steatohepatitis (NASH). One to 2 weeks of treatment with SofPulse appeared to counteract several of the disease signs associated with NASH-associated liver damage.
Male mice, 8 weeks old were placed on an MCD diet (methionine-choline deficient diet) for either 7 or 14 days. Feeding mice a diet deficient in methionine and choline is a commonly used mouse model to study the inflammation and hepatic ballooning associated with NASH. To determine if Endonovo’s non-invasive medical device could ameliorate the manifestations of a NASH induced diet, mice were exposed to either a proprietary electroceutical therapy system or a sham system during the duration of the MCD diet.
ENDV would be a great place to start if you’re looking to research potential companies that could be the answer to the opioid crisis.
Companies to put on your radar include: Endonovo Therapeutics, Inc. (ENDV), Aurora Cannabis (NYSE:ACB), Aphria, Inc. (NYSE:APHA), INSYS Therapeutics, Inc. (NASDAQ:INSY), and CV Sciences, Inc. (CVSI).
Endonovo Therapeutics, Inc. (ENDV)
Market Cap: $14.14M Share Price: $0.038
Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical? Therapies, announced a distribution agreement with Magniant, LLC for the distribution of Sofpulse, its non-invasive Electroceutical? Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.
Alan Collier, Endonovo Chief Executive Officer, stated, “We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our SofPulse device on a national level.”
Aurora Cannabis, Inc. (NYSE:ACB)
Market Cap: $7.19B Share Price: $7.49
Aurora Cannabis Inc. (ACB), just announced the official opening of its latest high-tech cannabis production facility in Lachute, Quebec; the company is calling it “Eau.”
At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America. It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world. Eau becomes Aurora’s second production facility in Quebec , the first being Aurora Vie, a 40,000 square foot indoor grow facility in Pointe Claire, Quebec .
Aphria, Inc. (NYSE:APHA)
Market Cap: $3.29B Share Price: $12.72
Aphria Inc. (APHA) announced an agreement with Rapid Dose Therapeutics Inc. that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT’s QuickStrip? innovative, proprietary delivery technology for both medical and adult-use cannabis market.
INSYS Therapeutics, Inc. (NASDAQ:INSY)
Market Cap: $605.09M Share Price: $8.15
NSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently reported financial results for its third quarter ended Sept. 30, 2018. The company achieved net revenue of $18.3 million in the third quarter of 2018.
CV Sciences, Inc. (CVSI)
Market Cap: $608.87M Share Price: $6.37
CVSI announced that it will be a Title Sponsor of the 25th anniversary of HIACON Conference on November 2-5, in Los Angeles, California. Produced by the Hemp Industries Association (HIA), HIACON will bring together over 400 attendees (cultivators, stakeholders, buyers), more than 55 speakers and industry thought leaders, and many other hemp and CBD sponsors to the Hilton Los Angeles Airport Hotel.
Important Disclaimer, Please Read:
The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.
The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.
Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. ENDV has paid forty-nine thousand dollars and twenty thousand restricted shares for corporate awareness services for the month of October, and continues to pay Regal to disseminate truthful and potentially material information regarding ENDV.
Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.
Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.
Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in ENDV can be found updated here: http://www.regalconsultingllc.com/disclaimer/.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eighty thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of ENDV in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC,For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC